- $566.45m
- $368.64m
- $0.43m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.92 | ||
| Price to Tang. Book | 2.92 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1,329.7 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -48.33% | ||
| Return on Equity | -46.63% | ||
| Operating Margin | -22518.54% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 5.8 | 8.19 | 4.41 | -0.07 | 0.43 | 41.67 | n/a | -47.15% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
Directors
- Mitchel Sayare NEC (73)
- Vipin Garg PRE (63)
- Richard Eisenstadt CFO (63)
- M. Scot Roberts CSO (62)
- M. Scott Harris OTH (67)
- David Drutz IND (82)
- John Gill IND (69)
- Philip Hodges IND (52)
- Diane Jorkasky IND (69)
- Wayne Pisano IND (66)
- Klaus Schafer IND (71)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 25th, 2005
- Public Since
- October 6th, 2005
- No. of Shareholders
- 181
- No. of Employees
- 59
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 70,895,286
- Address
- 910 Clopper Rd Ste 201S, GAITHERSBURG, 20878-1361
- Web
- https://altimmune.com/
- Phone
- +1 2406541450
- Contact
- Richard Eisenstadt
- Auditors
- Ernst & Young LLP
Upcoming Events for ALT
Altimmune Inc GLP-1-Based Therapeutics Summit
Q2 2024 Altimmune Inc Earnings Release
Altimmune Inc Annual Shareholders Meeting
Similar to ALT
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Altimmune share price?
As of Today at 19:02 UTC, shares in Altimmune are trading at $7.99. This share price information is delayed by 15 minutes.
How has the Altimmune share price performed this year?
Shares in Altimmune last closed at $7.99 and the price had moved by +73.32% over the past 365 days. In terms of relative price strength the Altimmune share price has outperformed the S&P500 Index by +39.97% over the past year.
What are the analyst and broker recommendations for Altimmune?
The overall consensus recommendation for Altimmune is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Altimmune dividend yield?
Altimmune does not currently pay a dividend.
Does Altimmune pay a dividend?
Altimmune does not currently pay a dividend.
When does Altimmune next pay dividends?
Altimmune does not currently pay a dividend.
How do I buy Altimmune shares?
To buy shares in Altimmune you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Altimmune?
As of the previous close price of $7.99, shares in Altimmune had a market capitalisation of $566.45m.
Where are Altimmune shares listed?
Here are the trading details for Altimmune:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ALT
What kind of share is Altimmune?
Based on an overall assessment of its quality, value and momentum Altimmune is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Altimmune share price forecast for 2024?
The analyst consensus target price for shares in Altimmune is $21.25. That is 165.96% above the last closing price of $7.99.
Analysts covering Altimmune currently have a consensus Earnings Per Share (EPS) forecast of -$1.00 for the next financial year.
What is the trend in the Altimmune share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Altimmune. Over the past six months, its share price has outperformed the S&P500 Index by +156.42%.
As of the last closing price of $7.99, shares in Altimmune were trading +37.39% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Altimmune PE Ratio?
The Altimmune PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $7.99.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Altimmune?
Altimmune's management team is headed by:
- Mitchel Sayare - NEC
- Vipin Garg - PRE
- Richard Eisenstadt - CFO
- M. Scot Roberts - CSO
- M. Scott Harris - OTH
- David Drutz - IND
- John Gill - IND
- Philip Hodges - IND
- Diane Jorkasky - IND
- Wayne Pisano - IND
- Klaus Schafer - IND